BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26116425)

  • 21. Erdosteine for COPD exacerbations.
    Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
    Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
    Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
    Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
    Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [ Erdosteine (Mucodox), oral administration].
    J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
    Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
    Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
    Murali PM; Rajasekaran S; Paramesh P; Krishnarajasekar OR; Vasudevan S; Nalini K; Lakshmisubramanian S; Deivanayagam CN
    Respir Med; 2006 Jan; 100(1):39-45. PubMed ID: 15905081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
    Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
    Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
    Rennard SI; Schachter N; Strek M; Rickard K; Amit O
    Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset.
    Calverley PMA; Papi A; Page C; Rogliani P; Dal Negro RW; Cazzola M; Cicero AF; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1909-1920. PubMed ID: 36034589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease.
    Votto JJ; Bowen JB; Barton RW; Thrall RS
    J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):329-34. PubMed ID: 18800883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
    Aubier M; Berdah L
    Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.